Janux Therapeutics (JANX) Research & Development (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Research & Development of $26.8 million for Q1 2026, up 7.02% year-over-year from $25.1 million in Q1 2025, and down 15.01% quarter-over-quarter from $31.5 million in Q4 2025.
Janux Therapeutics (JANX) Research & Development (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Research & Development for 7 consecutive years, with $26.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 7.02% year-over-year to $26.8 million; the TTM figure through Mar 2026 stood at $127.7 million (up 60.83% YoY), while the FY2025 annual figure was $125.9 million, up 84.09% from the prior year.
- Research & Development fell to $26.8 million in Q1 2026 per JANX's latest filing, from $31.5 million in the prior quarter.
- Across five years, Research & Development topped out at $34.7 million in Q2 2025 and bottomed at $10.2 million in Q1 2022.
- Historically, Research & Development has averaged $19.4 million across 5 years, with a median of $15.4 million in 2022.
- Annual changes were most pronounced in 2022 — Research & Development soared 429.04% — and 2023, when it declined 20.69%.
- Janux Therapeutics' Research & Development stood at $15.4 million in 2022, then slipped by 20.69% to $12.2 million in 2023, then surged by 69.97% to $20.8 million in 2024, then surged by 51.63% to $31.5 million in 2025, then fell by 15.01% to $26.8 million in 2026.
- Business Quant data shows JANX's Research & Development at $26.8 million in Q1 2026, $31.5 million in Q4 2025, and $34.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 30.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.99 Mn |
| Mar 31, 2026 | 26.81 Mn |
| Dec 31, 2025 | 31.55 Mn |
| Sep 30, 2025 | 34.63 Mn |
| Jun 30, 2025 | 34.66 Mn |
| Mar 31, 2025 | 25.06 Mn |
| Dec 31, 2024 | 20.81 Mn |
| Sep 30, 2024 | 18.61 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | 14.07 Mn |
| Dec 31, 2023 | 12.24 Mn |
| Sep 30, 2023 | 11.89 Mn |
| Jun 30, 2023 | 14.92 Mn |
| Mar 31, 2023 | 15.87 Mn |
| Dec 31, 2022 | 15.43 Mn |
| Sep 30, 2022 | 13.74 Mn |
| Jun 30, 2022 | 14.09 Mn |
| Mar 31, 2022 | 10.18 Mn |
| Dec 31, 2021 | 11.17 Mn |
| Sep 30, 2021 | 8.41 Mn |